DIHYDROMYRICETIN ATTENUATES HIGH GLUCOSE-INDUCED CASPASE 3 EXPRESSION, ROS PRODUCTION AND INCREASES AMPK PHOSPHORYLATION IN PC12 CELLS

Shuo Wang1*, Lin Wang1*, Haijian Li1*, Shumei Wang1*, Zhenzhen Li1, Bao Li2*, Chunzhen Zhao1*

1 Laboratory of Applied Pharmacology, Weifang Medical University, Weifang 261053, China
2 Department of urology, Affiliated Hospital of Weifang Medical College

ABSTRACT:
Dihydromyricetin (DMY) has a protective effect on neural function under central nervous system dysfunction conditions. There is growing interest concerning the beneficial effects of DMY on treating diabetic neuropathy (DN). This study was carried to detect protective effects of DMY on high glucose (HG)-induced cell damage and related mechanisms. The effect of DMY on cell survival was detected by MTT assay. Caspase-3 and phosphorylated AMPK-activated protein kinase (AMPK) was evaluated by Western blotting. The effects of DMY and AMPK agonist AICAR on ROS production was determined. Our results showed that DMY treatment protect against HG-induced cell damage. DMY treatment significantly reduced the expression of caspase-3 and phosphorylated AMPK. ROS production was inhibited by DMY or AMPK agonist AICAR treatment. These studies demonstrate that DMY may inhibit ROS production, caspase-3 expression through AMPK pathway.

Keywords: dihydromyricetin, caspase, oxidative stress

Introduction
Diabetes mellitus is a major cause of high morbidity and mortality in the world. Diabetic neuropathy (DN) is one of the most common diabetes-related complications leading to cognitive impairment, motor and sensory dysfunction[1]. The importance of DN is being recognized increasingly. Oxidative stress, impaired cerebral insulin signaling systems are considered as being closely related to DN development[2]. Many evidence have reported that overproduction of reactive oxygen species (ROS) contributed to neural cell apoptosis and inhibition of oxidation may block the progression of DN[3].

Dihydromyricetin (DMY), a flavonoid compound, was isolated from the leaves of Ampelopsis grossedentata[4]. It has been reported to possess multiple pharmacological activities including anti-inflammatory[5], anti-oxidative[6], anticancer[7] and hepatoprotective effects[8]. Recent data supported dihydromyricetin attenuated methylglyoxal induced- oxidative stress in PC12 cells[9].

Dihydromyricetin treatment can improve Aβ induced cognitive impairment and reverse progressive neuropathology in a mouse model of Alzheimer’s disease[10]. However, the effects of DMY on hyperglycemia neural injury and related mechanisms have not been clearly studied.

The aim of the present study was to investigate the protective effects of DMY on high glucose-induced cell damage in cultured PC12 cells. We further examined whether DMY can affect high glucose-induced caspase-3 expression, ROS production and AMPK phosphorylation.

Materials and Methods
Reagents
Dihydromyricetin (purity ≥ 98%) was purchased from Sigma-Aldrich. ROS production was measured by using a ROS assay kit (Nanjing Jiancheng Bioengineering Institute, China). Antibodies against phospho-AMPK, cleaved caspase 3 was purchased from Boster Bio Tech (Wuhan, China). Antibodies
against GAPDH were obtained from Beyotime, Nanjing, China.

**Cell Culture**

PC12 cells were cultured in DMEM medium containing 10% fetal bovine serum under conditions of 37 °C in humidified air containing 5% CO₂. The cultured medium was changed every 48 hours and the cells in the exponential phase of growth were used in all experiments.

**Cell viability detection**

Cell viability was evaluated by a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) detection assay. PC12 cells were seeded in 96-well plates. Cells were pretreated with different conditions of Dihydromyricetin (10, 20, 40 μM) for 1 h and treated with high glucose with concentration of 100 mM for 48 h. MTT (5 mg/mL) was added to each well, and the cells were incubated for 4 h at incubator of 37 °C. The medium was removed and dimethyl sulfoxide (DMSO) was added to the wells. The absorbance was measured at 570 nm using multiscan spectrum. Cell viability was expressed normalized to percentage of non-treated control cells.

**Intracellular ROS detection assay**

Intracellular ROS production was evaluated by 2,7-dichlorofluorescin diacetate (DCFH-DA) fluorescent probe detection assay. PC12 cells were seeded in 24-well plates and pretreated with DMY 20 μM for 1 h or AICAR 10 nM and exposed to high glucose with concentrations of 100 mM for 48 h. Then cell viability was detected by MTT detection assay. HG induced cell damage significantly compared to the control group. DMY with concentrations of 10, 20, 40 μM can increase cell survival significantly as compared to HG group (Fig.1, P < 0.01).

**Western Blot Analysis**

PC12 cells were harvested and washed with ice-cold PBS, and the cellular lysates were prepared. Protein concentrations were determined by BCA assay. The protein samples were subjected to electrophoresis on 10-12% SDS polyacrylamide gels and transferred onto a nitrocellulose membrane. Then the membrane was blocked with 7.5% nonfat milk, and incubated with anti-cleaved caspase 3, anti-phospho-AMPK and anti-GAPDH antibodies overnight. Then the blots were incubated with anti-rabbit IRDye700DX®-conjugated antibody or anti-mouse IRDye800DX®-conjugated antibody. The signals were scanned by an Odyssey infrared imaging system. Protein bands were quantitatively evaluated by Quantity One® analysis software. The ratio to confidence reference items was calculated.

**Statistical Analysis**

All data were expressed as mean ± SD. The significance of differences among three or more groups was performed using One-way ANOVA followed by Bonferroni’s post hoc test (SPSS 15.0 for Windows, SPSS inc., USA). P < 0.05 was considered statistically significant.

**Results**

**DMY attenuated HG-induced PC12 cell damage**

To investigate protective effect of DMY in high glucose-induced neural cell damage model, PC12 cells were pretreated with DMY with different concentrations of 10, 20, 40 μM and exposed to high glucose with concentrations of 100 mM for 48 h. Then cell viability was detected by MTT detection assay. HG induced cell damage significantly compared to the control group. DMY with concentrations of 10, 20, 40 μM can increase cell survival significantly as compared to HG group (Fig.1, P < 0.01).

**DMY decreased HG-induced caspase-3 expression in PC12 cells**

Apoptosis related protein caspase 3 was detected by Western blotting and protective effect of DMY on caspase-3 expression was evaluated. As shown in Fig.2, compared to control group, cleaved caspase-3 protein expression increased significantly. 20 μM of DMY can significantly reduced caspase-3 expression in PC12 cells compared to HG group (Fig.2A and 2B, P < 0.05).

**Effect of DMY on HG-induced intracellular ROS production and AMPK activation**

Many studies have reported that ROS contributed to HG-induced PC12 cell injury. Here we struggled to demonstrate whether DMY would affect the elevated level of ROS and related mechanisms in HG-treated PC12 cells. Our results showed that DMY significantly reduced HG-induced ROS production in PC12 cells. Also we found DMY can recover HG-induced inhibition of AMPK.
Shuo Wang et al.,

Phosphonylation (Fig. 2, \( P < 0.05 \)). As compared with HG group, AMPK agonist AICAR 10 nM can significantly reduced HG-induced ROS level in PC12 cells (Fig. 3, \( P < 0.01 \)).

**Fig. 1:** Effect of DMY in PC12 cells after HG exposure. Cell viability was evaluated by MTT detection assay. PC12 cells are pretreated with DMY for 1 h and then exposed to HG 100 mM for 48 h. Data are expressed as mean ± SD. **\( P < 0.01 \)** compared to control group. **##\( P < 0.01 \), #\( P < 0.05 \) compared to HG group.

**Fig. 2:** Effect of DMY on caspase-3 expression and AMPK phosphorylation in PC12 cells. PC12 cells are pretreated with DMY 20 \( \mu \)M for 1 h and then exposed to HG for 48 h (A). The density of caspase 3 and p-AMPK was determined by Western blotting and the ratio to GAPDH was calculated. *\( P < 0.05 \) compared to control group, #\( P < 0.05 \) compared to HG group.

**Fig. 3:** Effect of DMY and AMPK agonist on ROS production in PC12 cells. PC12 cells are pretreated with DMY 20 \( \mu \)M or AMPK agonist AICAR 10 nM for 1 h and then exposed to HG for 48 h. Intracellular ROS generation in PC12 cells was determined using a detection assay. Values are expressed as ratio of control group and reported as mean ± SD. **##\( P < 0.01 \)** compared to HG group.

**Discussion**

In the present study, we reported that DMY pretreatment protected against HG-induced cell damage, and reduced the expression of caspase-3 and phosphorylated AMPK. DMY reduced ROS production possibly through AMPK pathway.

The flavonoids are a large class of powerful antioxidative compounds that are mainly found in fruits, tea and other plant-derived materials[11]. Many studies have demonstrated the effects of flavonoids and their metabolites on cancer, diabetes mellitus and Alzheimer’s disease[12]. Dihydromyricetin has been showed a potential neuroprotective effect against oxidative stress-induced and amyloid-induced neuronal cell injury[13]. As a flavonoid compound, isolated from traditional southern Chinese herb Ampelopsis grossedentata, DMY possessed neuroprotective effects against oxidative stress in neurodegenerative diseases[14]. It was reported that DMY significantly reduced oxidative stress and inhibited microglial inflammation in transgenic mouse model of Aβ[15]. Moreover, DMY also decreased oxidative stress induced cell injury in a concentration-dependent manner[16]. Consistent
with previous studies, our results showed DMY protected PC12 neural cells against HG-induced cell cytotoxicity.

It’s well known that imbalance of Bax/Bcl-2 leads to the release of cytochrome C, caspase-3 activation and subsequent cell apoptosis in neural cells\textsuperscript{[17]}. Caspase-3 plays a pivotal role as a final stage of apoptosis\textsuperscript{[18]}. It was reported that increased caspase-3 prompted apoptosis in PC12 cells\textsuperscript{[19]}. Thus, our study found that DMY pretreatment is able to suppress the activation of capase-3 in PC12 cells.

Previous studies showed that hyperglycemia-induced intracellular ROS production and inhibition of AMPK phosphorylation\textsuperscript{[20]}. We observed that the influences of DMY on inhibition of ROS production and activation of AMPK phosphorylation. Since AMPK signaling pathway is a crucial pathway involved in cell apoptosis. AMPK agonist also have similar protective effect with DMY treatment in HG-induced ROS level. It indicated that DMY might reduce cell damage and ROS production through AMPK pathway. Our study supported the AMPK signaling pathway involved in the HG-induced PC12 cell apoptosis and cytotoxicity.

In conclusion, our data highlight the activation of AMPK signaling pathway as a potential mechanism by which DMY protects PC12 cells from HG-induced ROS production and cell apoptosis. These results may suggest that DMY therapy could be employed as a promising agent in prevention therapy for diabetic neuropathy.

Acknowledgement

This work was partly supported by Science and Technology Development Program of Traditional Chinese Medicine in Shandong Province (2017-207), Project of Shandong Province Higher Educational Science and Technology Program (J17KA256 and J18KA280), and Science and technology development project foundation of Weifang (2017YX063), Natural Science Foundation of Shandong Province (ZR2016HL12).

References

1. Semprini R, Martorana A, Ragonese M, Motta C. Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2. Minerva Med. 2018, 109(5): 358-362.
2. Etienne I, Magaliñæs LVB, Cardoso SA, de Freitas RB, de Oliveira GP, Palotás A, Lima LM. Oxidative stress markers in cognitively intact patients with diabetic neuropathy. Brain Res Bull. 2019, 150: 196-200.
3. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol. 2014, 2014: 674987.
4. Huang B, Li Y, Yao Y, Shu W, Chen M. Dihydromyricetin from ampelopsis grossedentata protects against vascular neointimal formation via induction of TR3. Eur J Pharmacol. 2018, 838: 23-31.
5. Zhang X, Li X, Fang J, Hou X, Fang H, Guo F, Li F, Chen A, Huang S. (2R,3R) Dihydromyricetin inhibits osteoclastogenesis and bone loss through scavenging LPS-induced oxidative stress and NF-κB and MAPKs pathways activating. J Cell Biochem. 2018, 119(11): 8981-8995.
6. Ling H, Zhu Z, Yang J, He J, Yang S, Wu D, Feng S, Liao D. Dihydromyricetin improves type 2 diabetes-induced cognitive impairment via suppressing oxidative stress and enhancing brain-derived neurotrophic factor-mediated neuroprotection in mice. Acta Biochim Biophys Sin (Shanghai). 2018, 50(3): 298-306.
7. Wang Z, Sun X, Feng Y, Liu X, Zhou L, Sui H, Ji Q, E Q, Chen J, Wu L, Li Q. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells. Anticancer Drugs. 2017, 28(3): 281-288.
8. Qiu P, Dong Y, Li B, Kang XJ, Gu C, Zhu T, Luo YY, Pang MX, Du WF, Ge WH. Dihydromyricetin modulates p62 and autophagy crosstalk with the Keap-1/Nrf2 pathway to alleviate ethanol-induced hepatic injury. Toxicol Lett. 2017, 274: 31-41.
9. Jiang B, Le L, Pan H, Hu K, Xu L, Xiao P. Dihydromyricetin ameliorates the oxidative stress response induced by methyglyoxal via the AMPK/GLUT4 signaling pathway in PC12 cells. Brain Res Bull. 2014, 109: 117-26.
10. Sun P, Yin JB, Liu LH, Guo J, Wang SH, Qu CH, Wang CX. Protective role of Dihydromyricetin in Alzheimer's disease rat model associated with activating AMPK/SIRT1 signaling pathway. Biosci Rep. 2019, 39(1). pii: BSR20180902.
11. Zheng YZ, Deng G, Guo R, Fu ZM, Chen DF. The influence of the H5⋯OC4 intramolecular hydrogen-bond (IHB) on the antioxidative activity of flavonoid. Phytochemistry. 2019, 160: 19-24.
12. Bai L, Li X, He L, Zheng Y, Lu H, Li J, Zhong L, Tong R, Jiang Z, Shi J, Li J. Antidiabetic Potential of
13. Jia L, Wang Y, Sang J, Cui W, Zhao W, Wei W, Chen B, Lu F, Liu F. Dihydromyricetin Inhibits α-Synuclein Aggregation, Disrupts Preformed Fibrils, and Protects Neuronal Cells in Culture against Amyloid-Induced Cytotoxicity. J Agric Food Chem. 2019, 67(14): 3946-3955.

14. Ren ZX, Zhao YF, Cao T, Zhen XC. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson’s disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol Sin. 2016, 37(10): 1315-1324.

15. Li C, Meng P, Zhang BZ, Kang H, Wen HL, Schluesener H, Cao ZW, Zhang ZY. Computer-aided identification of protein targets of four polyphenols in Alzheimer’s disease (AD) and validation in a mouse AD model. J Biomed Res. 2019, 33(2): 101-112.

16. Zhou DZ, Sun HY, Yue JQ, Peng Y, Chen YM, Zhong ZJ. Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NF-κB signalling in human melanoma cells. Free Radic Res. 2017, 51(5): 517-528.

17. Aminzadeh A. Protective effect of tropisetron on high glucose induced apoptosis and oxidative stress in PC12 cells: roles of JNK, P38 MAPKs, and mitochondria pathway. Metab Brain Dis. 2017, 32(3): 819-826.

18. Namazi Sarvestani N, Saberi Firouzi S, Falak R, Karimi MY, Davoodzadeh Gholami M, Rangbar A, Hosseini A. Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress, apoptosis and inflammation pathways. Metab Brain Dis. 2018, 33(4): 1293-1306.

19. Veluthakal R, Arora DK, Goalstone ML, et al. Metabolic stress induces caspase-3 mediated degradation and inactivation of farnesyl and geranylgeranyl transferase activities in pancreatic β-cells. Cell Physiol Biochem, 2016, 39(6): 2110-2120.

20. Peng Y, Liu J, Shi L, et al. Mitochondrial dysfunction precedes depression of AMPK/AKT signaling in insulin resistance induced by high glucose in primary cortical neurons. J Neurochem, 2016, 137(5): 701-713.